259 related articles for article (PubMed ID: 34021949)
1. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
2. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
[TBL] [Abstract][Full Text] [Related]
3. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
Srivastava T; Zwick DL; Rothberg PG; Warady BA
Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
[TBL] [Abstract][Full Text] [Related]
7. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.
Nieto-Rios JF; Gómez de Los Ríos SM; Serna-Higuita LM; Ocampo-Kohn C; Aristizabal-Alzate A; Gálvez-Cárdenas KM; Zuluaga-Valencia GA
Colomb Med (Cali); 2016 Dec; 47(4):196-202. PubMed ID: 28293043
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
10. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
11. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
[TBL] [Abstract][Full Text] [Related]
13. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
14. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
15. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
16. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
17. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
18. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series.
Puliyanda DP; Jordan SC; Kim IK; Patel M; Murthy A; Huang E; Zhang X; Reinsmoen N; Kamil ES; Toyoda M
Pediatr Transplant; 2021 Dec; 25(8):e14113. PubMed ID: 34418254
[TBL] [Abstract][Full Text] [Related]
19. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
